Dubai Investments PJSC

Dubai Investments announced an 18% cash dividend, totaling AED 765.36 million, for the financial year ending December 31, 2024, which was approved at the 29th Annual General Meeting on April 16, 2025. The company reported a net profit before tax of AED 1.3 billion for 2024, a 21% increase from the previous year, reflecting its strategic growth and operational excellence. The AGM also approved a new Dividend Distribution Policy. Dubai Investments, established in 1995, is a UAE-based multi-asset investment group with a diverse portfolio in sectors such as real estate, manufacturing, and healthcare, and aims to generate sustainable financial returns and drive growth through strategic investments.

Globalpharma, a leading pharmaceutical manufacturer in the UAE and a subsidiary of Dubai Investments PJSC, has partnered with India's ZIM Laboratories to introduce EU-certified Oral Dispersible Film (ODF) technology to its product range. This technology, which meets high international quality and safety standards, was announced at the AIM Congress 2025 in Dubai. The collaboration aims to enhance the UAE's role in global pharmaceutical innovation and improve healthcare solutions. The agreement was signed by key representatives from both companies and witnessed by notable officials. Globalpharma's leaders highlighted the UAE's growing influence in pharmaceutical manufacturing and discussed industry trends at the congress. The partnership with ZIM Labs is seen as a significant step in advancing patient-centric treatment options and strengthening the region's pharmaceutical capabilities. ODFs are thin, fast-dissolving strips that improve medication compliance, especially for children, the elderly, and those with swallowing difficulties. Globalpharma plans to produce these innovative treatments locally, setting a new standard for pharmaceutical manufacturing in the region.

The disclosure clarifies the process for shareholders to delegate someone to attend the General Assembly on their behalf. Shareholders can delegate individuals who are not board members, company staff, or employees of a securities brokerage company. The delegated person can represent multiple shareholders but cannot exceed 5% of the company's issued capital. Legal representatives must represent those lacking legal capacity. The shareholder's signature on the power of attorney must be approved by specific entities such as a Notary Public, Chamber of Commerce, a bank where the shareholder has an account, licensed financial markets, or any licensed notarial entity in the UAE. The proxy form should include the shareholder's name, contact number, and the approving authority. For further inquiries, contact details are provided.

Dubai Investments PJSC reported a net profit before tax of AED 1.3 billion for the fiscal year ending December 31, 2024, marking a 21% increase from the previous year. The company's total income reached AED 4.66 billion, driven by strong real estate sales and increased rental income. Total assets grew to AED 22.10 billion by the end of 2024. The board proposed an 18% cash dividend for 2024, reflecting a commitment to shareholder value. The company plans to focus on growth by evaluating investment opportunities, strategic divestments, and potential IPOs to enhance market presence and shareholder value.

Dubai Investments announced that its subsidiaries, GlobalPharma and Emirates Float Glass (EFG), have signed Memorandums of Understanding (MOUs) during a meeting in Doha, Qatar, aimed at promoting industrial growth and sustainable development. The agreements, supported by the Ministry of Industry and Advanced Technology, involve collaboration with various regional partners. GlobalPharma signed an MOU with Morocco's Zenith Pharma to enhance pharmaceutical production, focusing on critical medications, with an investment of over $50 million. Emirates Float Glass signed an MOU to supply float glass to a regional company, enhancing cooperation in the glass manufacturing sector. GlobalPharma was recognized for its contributions to pharmaceutical research and development.